CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation

NYSE:CRL • US1598641074

Current stock price

163.84 USD
-2.95 (-1.77%)
At close:
163.84 USD
0 (0%)
After Hours:

This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. CRL Profitability Analysis

1.1 Basic Checks

  • CRL had positive earnings in the past year.
  • In the past year CRL had a positive cash flow from operations.
  • Of the past 5 years CRL 4 years were profitable.
  • In the past 5 years CRL always reported a positive cash flow from operatings.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • With a Return On Assets value of -2.02%, CRL perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
  • The Return On Equity of CRL (-4.56%) is comparable to the rest of the industry.
  • The Return On Invested Capital of CRL (6.60%) is better than 77.19% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CRL is below the industry average of 11.01%.
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROIC 6.6%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • Looking at the Operating Margin, with a value of 12.51%, CRL is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
  • CRL's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 34.98%, CRL is doing worse than 63.16% of the companies in the same industry.
  • CRL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.51%
PM (TTM) N/A
GM 34.98%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CRL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
  • Compared to 1 year ago, CRL has less shares outstanding
  • CRL has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CRL has a worse debt to assets ratio.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 2.37 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • CRL's Altman-Z score of 2.37 is fine compared to the rest of the industry. CRL outperforms 66.67% of its industry peers.
  • The Debt to FCF ratio of CRL is 4.13, which is a neutral value as it means it would take CRL, 4.13 years of fcf income to pay off all of its debts.
  • CRL has a Debt to FCF ratio of 4.13. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
  • CRL has a Debt/Equity ratio of 0.68. This is a neutral value indicating CRL is somewhat dependend on debt financing.
  • CRL has a worse Debt to Equity ratio (0.68) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Altman-Z 2.37
ROIC/WACC0.62
WACC10.57%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.29, CRL is not doing good in the industry: 80.70% of the companies in the same industry are doing better.
  • CRL has a Quick Ratio of 1.02. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.02, CRL is doing worse than 80.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.02
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CRL Growth Analysis

3.1 Past

  • The earnings per share for CRL have decreased by -0.39% in the last year.
  • Measured over the past 5 years, CRL shows a small growth in Earnings Per Share. The EPS has been growing by 4.78% on average per year.
  • Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -0.85% in the last year.
  • CRL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.55% yearly.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%

3.2 Future

  • Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.56% on average per year.
  • Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.67% on average per year.
EPS Next Y8.35%
EPS Next 2Y9.28%
EPS Next 3Y9.35%
EPS Next 5Y11.56%
Revenue Next Year-1.8%
Revenue Next 2Y0.59%
Revenue Next 3Y1.84%
Revenue Next 5Y2.67%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. CRL Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.94, the valuation of CRL can be described as correct.
  • Based on the Price/Earnings ratio, CRL is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
  • CRL is valuated rather cheaply when we compare the Price/Earnings ratio to 26.54, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 14.71, which indicates a correct valuation of CRL.
  • Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 92.98% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CRL to the average of the S&P500 Index (21.68), we can say CRL is valued slightly cheaper.
Industry RankSector Rank
PE 15.94
Fwd PE 14.71
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • CRL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CRL is cheaper than 91.23% of the companies in the same industry.
  • 85.96% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.59
EV/EBITDA 11.22
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)1.91
PEG (5Y)3.34
EPS Next 2Y9.28%
EPS Next 3Y9.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRL Dividend Analysis

5.1 Amount

  • CRL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRL Fundamentals: All Metrics, Ratios and Statistics

CHARLES RIVER LABORATORIES

NYSE:CRL (4/29/2026, 8:05:40 PM)

After market: 163.84 0 (0%)

163.84

-2.95 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength17.39
Industry Growth53.42
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners110.65%
Inst Owner Change-0.17%
Ins Owners0.84%
Ins Owner Change5.84%
Market Cap8.08B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.55 (26.07%)
Short Float %9.54%
Short Ratio4.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)0.13%
PT rev (3m)-1.01%
EPS NQ rev (1m)0.69%
EPS NQ rev (3m)-23.99%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)1.32%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-1.84%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-3.45%
Valuation
Industry RankSector Rank
PE 15.94
Fwd PE 14.71
P/S 2.01
P/FCF 15.59
P/OCF 10.96
P/B 2.55
P/tB 133.88
EV/EBITDA 11.22
EPS(TTM)10.28
EY6.27%
EPS(NY)11.14
Fwd EY6.8%
FCF(TTM)10.51
FCFY6.41%
OCF(TTM)14.95
OCFY9.12%
SpS81.38
BVpS64.14
TBVpS1.22
PEG (NY)1.91
PEG (5Y)3.34
Graham Number121.801 (-25.66%)
Profitability
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROCE 8.35%
ROIC 6.6%
ROICexc 6.84%
ROICexgc 14.71%
OM 12.51%
PM (TTM) N/A
GM 34.98%
FCFM 12.91%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Debt/EBITDA 2.36
Cap/Depr 54.34%
Cap/Sales 5.46%
Interest Coverage 4.94
Cash Conversion 81.47%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.02
Altman-Z 2.37
F-Score5
WACC10.57%
ROIC/WACC0.62
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y8.35%
EPS Next 2Y9.28%
EPS Next 3Y9.35%
EPS Next 5Y11.56%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year-1.8%
Revenue Next 2Y0.59%
Revenue Next 3Y1.84%
Revenue Next 5Y2.67%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year25.17%
EBIT Next 3Y11.49%
EBIT Next 5Y11.35%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%

CHARLES RIVER LABORATORIES / CRL Fundamental Analysis FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


Can you provide the profitability details for CHARLES RIVER LABORATORIES?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 15.94 and the Price/Book (PB) ratio is 2.55.


What is the financial health of CHARLES RIVER LABORATORIES (CRL) stock?

The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.